As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.
Only one in three people with major depressive disorder achieves remission after their first antidepressant, leaving many to continue to experience life-impacting symptoms such as disrupted sleep, changes in weight and appetite and trouble concentrating. Learn why Johnson & Johnson is working to help more patients achieve remission.
Johnson & Johnson launched this competition with one goal: to accelerate the development of next-generation surgical technologies. Meet this year’s three awardees and learn about their innovations.